Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Veracyte (VCYT) Equity Average (2016 - 2025)

Veracyte's Equity Average history spans 13 years, with the latest figure at $1.3 billion for Q4 2025.

  • For Q4 2025, Equity Average rose 9.15% year-over-year to $1.3 billion; the TTM value through Dec 2025 reached $1.3 billion, up 9.15%, while the annual FY2025 figure was $1.2 billion, 11.96% up from the prior year.
  • Equity Average for Q4 2025 was $1.3 billion at Veracyte, up from $1.2 billion in the prior quarter.
  • Across five years, Equity Average topped out at $1.3 billion in Q4 2025 and bottomed at $697.7 million in Q1 2021.
  • The 5-year median for Equity Average is $1.1 billion (2023), against an average of $1.1 billion.
  • The largest annual shift saw Equity Average surged 326.09% in 2021 before it decreased 3.64% in 2022.
  • A 5-year view of Equity Average shows it stood at $1.1 billion in 2021, then decreased by 3.64% to $1.1 billion in 2022, then decreased by 1.19% to $1.0 billion in 2023, then grew by 12.1% to $1.2 billion in 2024, then grew by 9.15% to $1.3 billion in 2025.
  • Per Business Quant, the three most recent readings for VCYT's Equity Average are $1.3 billion (Q4 2025), $1.2 billion (Q3 2025), and $1.2 billion (Q2 2025).